Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 3/2014

01-09-2014 | Original Article

SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression

Authors: Gerardo Botti, Giosuè Scognamiglio, Laura Marra, Francesca Collina, Maurizio Di Bonito, Margherita Cerrone, Bruna Grilli, Annamaria Anniciello, Renato Franco, Franco Fulciniti, Paolo Antonio Ascierto, Monica Cantile

Published in: Virchows Archiv | Issue 3/2014

Login to get access

Abstract

The existence of a “metastasis gene signature” that predisposes primary breast cancer cells to metastasize to the lungs has been recently highlighted by gene expression profiling studies. The combination of genes responsible for this process includes genes encoding several metalloproteinases as well as the gene encoding SPARC (secreted protein acidic and rich in cysteine)/osteonectin. SPARC is involved in normal tissue remodeling as it regulates the deposition of extracellular matrix, but also plays a role in neoplastic transformation. Aberrant SPARC expression has been detected both in stromal cells associated with cancer and in cancer cells. The main aim of this study was to investigate whether or not SPARC might be involved in directing metastasis of other types of cancer to the lung. We constructed a tissue microarray containing lung metastases from a variety of primary tumors in different organs and used immunohistochemistry to assess SPARC expression. We found SPARC overexpressed mainly in lung metastases from melanoma. We then assessed the expression of SPARC mRNA and protein in metastatic melanoma from different anatomic sites and in their corresponding primary tumors, and found that it is overexpressed in lung metastases. Our data strongly support the hypothesis that SPARC is involved in directing melanoma metastases specifically to the lung, which underpins its potential as prognostic marker and novel target for specific therapy.
Literature
1.
Palmieri G, Capone M, Ascierto ML et al (2009) Main roads to melanoma. J Transl Med 14:86–102CrossRef
2.
3.
4.
Chlenski A, Cohn SL (2010) Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 21:55–65PubMedCrossRef
5.
Bellahcène A, Castronovo V (1995) Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 146:95–100PubMedCentralPubMed
6.
Jones C, Mackay A, Grigoriadis A et al (2004) Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Res 64:3037–45PubMedCrossRef
7.
Derosa CA, Furusato B, Shaheduzzaman S et al (2012) Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis 15:150–6PubMedCrossRef
8.
Yang E, Kang HJ, Koh KH et al (2007) Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121:567–75PubMedCrossRef
9.
Chlenski A, Liu S, Crawford SE et al (2002) SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62:7357–63PubMed
10.
Rempel SA, Golembieski WA, Fisher JL et al (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 53:149–60PubMedCrossRef
11.
Puolakkainen PA, Brekken RA, Muneer S (2004) Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2:215–24PubMed
12.
Sato N, Fukushima N, Maehara N (2003) SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22:5021–30PubMedCrossRef
13.
Said N, Frierson HF, Sanchez-Carbayo M et al (2013) Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest 123:751–66PubMedCentralPubMedCrossRef
14.
Di Martino JF, Lacayo NJ, Varadi M (2006) Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20:426–32CrossRef
15.
Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M (2008) Matricellular proteins produced by melanocytes and melanomas: In search for functions. Cancer Microenviron 1:93–102PubMedCentralPubMedCrossRef
16.
Botti G, Cerrone M, Scognamiglio G et al (2013) Microenvironment and tumor progression of melanoma: New therapeutic prospectives. J Immunotoxicol 10:235–52PubMedCrossRef
17.
Brekken RA, Puolakkainen P, Graves DC et al (2003) Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111:487–95PubMedCentralPubMedCrossRef
18.
19.
Ju X, Ertel A, Casimiro MC et al (2013) Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res 73:978–89PubMedCentralPubMedCrossRef
20.
de Souza CF, Xander P, Monteiro AC et al (2012) Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. PLoS One 7:e44800PubMedCentralPubMedCrossRef
21.
Navab R, Strumpf D, Bandarchi B et al (2011) Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 108:7160–5PubMedCentralPubMedCrossRef
22.
Watanabe T, Kobunai T, Tanaka T et al (2009) Gene expression signature and the prediction of lymph node metastasis in colorectal cancer by DNA microarray. Dis Colon Rectum 52:1941–8PubMedCrossRef
23.
van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–6CrossRef
24.
Brekken RA, Sage EH (2001) SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19:816–27PubMedCrossRef
25.
26.
Ledda F, Bravo AI, Adris S et al (1997) The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108:210–4PubMedCrossRef
27.
Massi D, Franchi A, Borgognoni L et al (1999) Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30:339–44PubMedCrossRef
28.
Fenouille N, Tichet M, Dufies M et al (2012) The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One 7:e40378PubMedCentralPubMedCrossRef
29.
Desai N, Trieu V, Damascelli B et al (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2:59–64PubMedCentralPubMedCrossRef
30.
Ledda MF, Adris S, Bravo AI et al (1997) Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3:171–6PubMedCrossRef
31.
Horie K, Tsuchihara M, Nakatsura T (2010) Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 101:913–9PubMedCrossRef
32.
33.
34.
Metadata
Title
SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression
Authors
Gerardo Botti
Giosuè Scognamiglio
Laura Marra
Francesca Collina
Maurizio Di Bonito
Margherita Cerrone
Bruna Grilli
Annamaria Anniciello
Renato Franco
Franco Fulciniti
Paolo Antonio Ascierto
Monica Cantile
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 3/2014
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-014-1616-4

Other articles of this Issue 3/2014

Virchows Archiv 3/2014 Go to the issue

Original Article

Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma

Letter to the Editor

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers

Original Article

Absence of caveolin-1 expression in carcinoma-associated fibroblasts of invasive micropapillary carcinoma of the breast predicts poor patient outcome

Original Article

Podoplanin expression in the cyst wall correlates with the progression of intraductal papillary mucinous neoplasm

Original Article

Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different

Original Article

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype